Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine.
IRCCS Ospedale Maggiore, Milano, Italy.
C
C
Ponticelli
A
A
Yussim
V
V
Cambi
C
C
Legendre
G
G
Rizzo
M
M
Salvadori
D
D
Kahn
S H
SH
Kashi
K
K
Salmela
L
L
Fricke
J
J
Garcia-Martinez
R
R
Lechler
U
U
Heemann
F
F
Monteon
J
J
Ortuño
J J
JJ
Amenabar
M
M
Arias
M L
ML
Nicholson
H
H
Sperschneider
D
D
Abendroth
C
C
Gracida
M
M
Lao
M S
MS
Sever
N
N
Lameire
A
A
Sanchez-Fructuoso
A
A
Bascì
G
G
Segoloni
J
J
Connolly
P
P
Altieri
J
J
Akoh
H
H
Prestele
D
D
Girault
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use*; D000077552:Basiliximab; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007239:Infections / Q000209:etiology; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D001379:Azathioprine; D011241:Prednisone